BioNTech ($BNTX) Insider Trading & Smart Money Activity
BioNTech SE ($BNTX) has 17 insider trades, 6 13F position changes and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($54.02M), net -$54.02M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 1
- Net insider $ (12 mo)
- -$54.02M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 6
- Analyst ratings on file
- 2
BNTX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 4 / 2 |
| Q3 2026 | 0 | 10 · $33.44M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 7 · $20.58M | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All BNTX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | Canaccord Genuity | Reiterates to Buy | PT $132 | Read | |||||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 36.21K sh | $3.45M | -9.5% | Read | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 27K sh | $2.49M | -2.0% | — | |||||
| Analyst | Morgan Stanley | Reiterates to Overweight | PT $114 | -6.9% | — | ||||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 24K sh | $2.30M | -6.9% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 21K sh | $2.03M | -7.0% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 72K sh | $7M | -1.8% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 17K sh | $1.64M | +0.1% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 17K sh | $1.66M | -4.9% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 32K sh | $3.14M | -3.1% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 34K sh | $3.34M | -2.9% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 34K sh | $3.35M | -1.5% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 27K sh | $2.66M | -1.6% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 39K sh | $3.86M | -2.4% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 30K sh | $2.98M | -0.2% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 46K sh | $4.63M | -2.3% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 33K sh | $3.23M | +1.1% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 30K sh | $2.89M | +2.6% | — | |||||
| Insider | Sahin UgurChief Executive Officer | Sell (Open-market sale) 10b5-1 | 34K sh | $3.35M | +0.6% | — | |||||
| 13F | T. Rowe Price Investment Management | Added | +1.37M sh | $524.35M | +2.9% | +1.4% | — | ||||
| 13F | T. Rowe Price Investment Management | Added | +1.37M sh | $544.91M | +2.9% | +1.4% | — | ||||
| 13F | Baker Bros. Advisors | Reduced | -249.18K sh | $11.14M | +2.9% | +1.4% | — | ||||
| 13F | Peak6 | Added | +18.05K sh | $3.86M | -1.2% | -1.3% | — | ||||
| 13F | Peak6 | Added | +18.05K sh | $4.01M | -1.2% | -1.3% | — | ||||
| 13F | Hudson Bay Capital Management | Reduced | -100K sh | $25.59M | -2.0% | -1.8% | — |
1W / 1M / 6M = how BNTX moved from the trade or filing date.
Insider trading in BNTX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Sahin Ugur | Chief Executive Officer | 17 | -$54.02M | Oct 9, 2026 |
Institutions moving BNTX (13F)
Analyst ratings on BNTX
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Reiterates | Buy | $136 → $132 | Read | ||||
| Morgan Stanley | Reiterates | Overweight | $115 → $114 | -6.9% | — |
Frequently asked questions
Are BNTX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 17 open-market sales worth $54.02M, a net -$54.02M.
What is the latest insider trade in BNTX?
Sahin Ugur, Chief Executive Officer filed a sell (open-market sale) of 36.21K sh worth $3.45M on Oct 9, 2026.
Which institutions changed their BNTX positions?
Recent 13F filers moving the stock include T. Rowe Price Investment Management, Peak6, Baker Bros. Advisors and Hudson Bay Capital Management.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.